Oruka Therapeutics, Inc. (ORKA) - Net Assets
Based on the latest financial reports, Oruka Therapeutics, Inc. (ORKA) has net assets worth $1.11 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.14 Billion) and total liabilities ($24.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Oruka Therapeutics, Inc. strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.11 Billion |
| % of Total Assets | 97.82% |
| Annual Growth Rate | 11.17% |
| 5-Year Change | 824.57% |
| 10-Year Change | 2026.39% |
| Growth Volatility | 251.86 |
Oruka Therapeutics, Inc. - Net Assets Trend (2005–2025)
This chart illustrates how Oruka Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ORKA market cap overview.
Annual Net Assets for Oruka Therapeutics, Inc. (2005–2025)
The table below shows the annual net assets of Oruka Therapeutics, Inc. from 2005 to 2025. Also explore how fast is Oruka Therapeutics, Inc. growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $471.93 Million | +23.47% |
| 2024-12-31 | $382.22 Million | +932.47% |
| 2023-12-31 | $37.02 Million | -11.17% |
| 2022-12-31 | $41.67 Million | -18.36% |
| 2021-12-31 | $51.04 Million | +9.72% |
| 2020-12-31 | $46.52 Million | +511.31% |
| 2019-12-31 | $7.61 Million | +26.16% |
| 2018-12-31 | $6.03 Million | -41.29% |
| 2017-12-31 | $10.28 Million | -53.70% |
| 2016-12-31 | $22.19 Million | -41.70% |
| 2015-12-31 | $38.07 Million | +158.26% |
| 2014-12-31 | $14.74 Million | -5.39% |
| 2013-12-31 | $15.58 Million | +435.98% |
| 2012-12-31 | $2.91 Million | -49.28% |
| 2011-12-31 | $5.73 Million | -15.34% |
| 2010-12-31 | $6.77 Million | -8.65% |
| 2009-12-31 | $7.41 Million | +239.51% |
| 2008-12-31 | $-5.31 Million | -107.85% |
| 2007-12-31 | $67.66 Million | -3.13% |
| 2006-12-31 | $69.84 Million | +23.04% |
| 2005-12-31 | $56.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oruka Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 13850200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $49.00K | 0.01% |
| Other Comprehensive Income | $546.00K | 0.12% |
| Other Components | $660.49 Million | 139.96% |
| Total Equity | $471.93 Million | 100.00% |
Oruka Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Oruka Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rayonier Inc
NYSE:RYN
|
$6.06 Billion |
|
Chailease Holding Co Ltd
TW:5871
|
$6.07 Billion |
|
Liquidia Technologies Inc
NASDAQ:LQDA
|
$6.07 Billion |
|
Yapi ve Kredi Bankasi AS
IS:YKBNK
|
$6.08 Billion |
|
Loar Holdings Inc.
NYSE:LOAR
|
$6.05 Billion |
|
MGIC Investment Corp
NYSE:MTG
|
$6.05 Billion |
|
Fastighets AB Balder (publ)
ST:BALD-B
|
$6.05 Billion |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
$6.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oruka Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 382,221,000 to 471,930,000, a change of 89,709,000 (23.5%).
- Net loss of 105,433,000 reduced equity.
- New share issuances of 671,000 increased equity.
- Other comprehensive income increased equity by 587,000.
- Other factors increased equity by 193,884,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-105.43 Million | -22.34% |
| Share Issuances | $671.00K | +0.14% |
| Other Comprehensive Income | $587.00K | +0.12% |
| Other Changes | $193.88 Million | +41.08% |
| Total Change | $- | 23.47% |
Book Value vs Market Value Analysis
This analysis compares Oruka Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 9.04x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $249501.12 | $93.55 | x |
| 2006-12-31 | $246298.97 | $93.55 | x |
| 2007-12-31 | $230179.63 | $93.55 | x |
| 2008-12-31 | $-1271052.63 | $93.55 | x |
| 2009-12-31 | $9480.93 | $93.55 | x |
| 2010-12-31 | $7221.24 | $93.55 | x |
| 2011-12-31 | $5182.64 | $93.55 | x |
| 2012-12-31 | $1977.55 | $93.55 | x |
| 2013-12-31 | $2730.16 | $93.55 | x |
| 2014-12-31 | $1087.17 | $93.55 | x |
| 2015-12-31 | $1307.48 | $93.55 | x |
| 2016-12-31 | $528.71 | $93.55 | x |
| 2017-12-31 | $212.76 | $93.55 | x |
| 2018-12-31 | $94.08 | $93.55 | x |
| 2019-12-31 | $69.12 | $93.55 | x |
| 2020-12-31 | $9.88 | $93.55 | x |
| 2021-12-31 | $3.67 | $93.55 | x |
| 2022-12-31 | $2.89 | $93.55 | x |
| 2023-12-31 | $2.57 | $93.55 | x |
| 2024-12-31 | $22.77 | $93.55 | x |
| 2025-12-31 | $10.35 | $93.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oruka Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-22.34%) is above the historical average (-74.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -126.16% | -13139.63% | 0.01x | 1.90x | $-77.29 Million |
| 2006 | -190.11% | -3415.05% | 0.02x | 2.64x | $-139.76 Million |
| 2007 | -18.18% | -26.25% | 0.39x | 1.78x | $-19.07 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.90 Million |
| 2009 | -123.29% | 0.00% | 0.00x | 1.26x | $-9.88 Million |
| 2010 | -124.35% | 0.00% | 0.00x | 1.20x | $-9.10 Million |
| 2011 | -93.58% | 0.00% | 0.00x | 1.13x | $-5.94 Million |
| 2012 | -148.61% | 0.00% | 0.00x | 1.10x | $-4.61 Million |
| 2013 | -44.54% | 0.00% | 0.00x | 1.10x | $-8.50 Million |
| 2014 | -65.73% | 0.00% | 0.00x | 1.09x | $-11.16 Million |
| 2015 | -30.06% | 0.00% | 0.00x | 1.04x | $-15.25 Million |
| 2016 | -74.09% | 0.00% | 0.00x | 1.11x | $-18.66 Million |
| 2017 | -179.95% | 0.00% | 0.00x | 1.20x | $-19.52 Million |
| 2018 | -131.52% | 0.00% | 0.00x | 1.13x | $-8.54 Million |
| 2019 | -72.04% | 0.00% | 0.00x | 1.12x | $-6.24 Million |
| 2020 | -20.93% | 0.00% | 0.00x | 1.08x | $-14.39 Million |
| 2021 | -37.85% | 0.00% | 0.00x | 1.08x | $-24.43 Million |
| 2022 | -23.82% | 0.00% | 0.00x | 1.03x | $-14.09 Million |
| 2023 | -14.42% | 0.00% | 0.00x | 1.02x | $-9.04 Million |
| 2024 | -21.90% | 0.00% | 0.00x | 1.04x | $-121.95 Million |
| 2025 | -22.34% | 0.00% | 0.00x | 1.04x | $-152.63 Million |
Industry Comparison
This section compares Oruka Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $201,571,196
- Average return on equity (ROE) among peers: -90.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | $1.11 Billion | -126.16% | 0.02x | $6.06 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $112.13 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $44.03 Million | -144.75% | 1.47x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.36 Billion |
| Arbutus Biopharma Corp (ABUS) | $76.58 Million | -43.75% | 0.24x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $723.96K | -677.23% | 9.41x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $8.92 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $732.79 Million | 30.90% | 0.62x | $4.75 Billion |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-… Read more